Cassava Sciences Inc vs PayPal Holdings, Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while PayPal Holdings, Inc. trades at $58.91 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 1058.2× Cassava Sciences Inc's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PYPL | |
|---|---|---|
Market Cap | $47.75M | $50.53B |
Sector | Health | Financials |
52-Week High | $4.64 | $76.13 |
52-Week Low | $0.87 | $39.08 |
Enterprise Value | -$34.93M | $52.68B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.
PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →